Quadrant Capital Group LLC Has $2.72 Million Stake in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Quadrant Capital Group LLC grew its position in Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 435.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 172,009 shares of the company’s stock after purchasing an additional 139,886 shares during the quarter. Quadrant Capital Group LLC’s holdings in Dr. Reddy’s Laboratories were worth $2,716,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of RDY. Robeco Institutional Asset Management B.V. boosted its holdings in Dr. Reddy’s Laboratories by 453.8% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company’s stock valued at $180,620,000 after acquiring an additional 9,373,412 shares during the period. Aikya Investment Management Ltd boosted its stake in Dr. Reddy’s Laboratories by 416.1% during the 4th quarter. Aikya Investment Management Ltd now owns 5,610,503 shares of the company’s stock valued at $88,590,000 after purchasing an additional 4,523,303 shares during the period. Vanguard Group Inc. increased its position in Dr. Reddy’s Laboratories by 397.2% in the 4th quarter. Vanguard Group Inc. now owns 4,896,185 shares of the company’s stock worth $77,311,000 after buying an additional 3,911,404 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of Dr. Reddy’s Laboratories by 462.1% during the fourth quarter. JPMorgan Chase & Co. now owns 2,814,710 shares of the company’s stock worth $44,444,000 after buying an additional 2,313,987 shares during the last quarter. Finally, Fisher Asset Management LLC grew its stake in shares of Dr. Reddy’s Laboratories by 402.5% in the fourth quarter. Fisher Asset Management LLC now owns 2,468,722 shares of the company’s stock worth $38,981,000 after acquiring an additional 1,977,419 shares during the last quarter. 3.85% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Nomura cut shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research note on Thursday, December 19th.

Dr. Reddy’s Laboratories Trading Down 6.6 %

Shares of RDY opened at $12.37 on Friday. The stock’s 50-day moving average price is $13.33 and its 200 day moving average price is $14.50. The company has a quick ratio of 1.38, a current ratio of 1.92 and a debt-to-equity ratio of 0.02. Dr. Reddy’s Laboratories Limited has a 12-month low of $12.36 and a 12-month high of $16.89. The firm has a market capitalization of $10.32 billion, a price-to-earnings ratio of 19.69 and a beta of 0.51.

Dr. Reddy’s Laboratories (NYSE:RDY) last issued its earnings results on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, beating analysts’ consensus estimates of $0.19 by $0.01. Dr. Reddy’s Laboratories had a return on equity of 17.87% and a net margin of 17.25%. As a group, research analysts predict that Dr. Reddy’s Laboratories Limited will post 0.8 earnings per share for the current year.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.